EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeted Metabolic Alterations in Prostate Cancer: A Promising Therapeutic Strategy

Zhanning Qu, Feng Hao iD, Zhaojun Li, Liu Yang, Hongxia Gao, Junying Li, Shuang Chen, Liguo Wang, Zhiming Xiu, Cheng Hu iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00341 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Zhanning Qu und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin 132013, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 199 Literaturangaben. Gefördert von: People's Government of Jilin Province, Inspection College of Jilin Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of prostate cancer (PCa) remains a major challenge due to the development of resistance to androgen receptor (AR)-targeted therapies and paclitaxel-based chemotherapeutic agents, highlighting the need for novel therapeutic approaches. Unlike the majority of tumor cells that depend on aerobic glycolysis (the Warburg effect) for energy production, early stage PCa primarily utilizes oxidative phosphorylation (OXPHOS), while advanced-stage PCa shifts to aerobic glycolysis. Consequently, targeting metabolic alterations specific to PCa may represent a promising therapeutic strategy. This review initially delineates the glucose metabolism phenotype characteristic of healthy prostate cells as well as primary and metastatic PCa cells, which underpin the development and progression of the disease. Subsequently, it elaborates on the roles and mechanisms of inhibitors targeting key enzymes involved in glycolysis and the synthesis of OXPHOS in the context of PCa treatment. Finally, the review discusses inhibitors that concurrently target both glycolysis and OXPHOS, potentially mitigating the compensatory pathways that support cancer cell survival. Collectively, this review contributes to a deeper understanding of metabolic alterations in PCa and informs the ongoing development of therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAntineoplastic AgentsHumansMaleOxidative PhosphorylationGlycolysisAnimalsMolecular Targeted TherapyWarburg Effect, Oncologic

Stichwörter der Autor:innen

glycolysismetabolic alterationoxidative phosphorylationprostate cancertarget therapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • College of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin 132013, China.
  • School of Medical Technology, Beihua university, Jilin City, Jilin 132013, China.
  • Gaomi municipal center for disease control and prevention, Gaomi City, Shandong 261500, China.
  • Department of Urology, Second Affiliated Hospital of Guangdong Medical University, Zhanjiang City, Guangdong 524031, China.
  • Jilin Collaborative Innovation Center for Antibody Engineering, Jilin Medical University, Jilin City, Jilin 132013, China.

ORCID-Profile: Feng Hao, Cheng Hu

Förderung

  • People's Government of Jilin Province
  • Inspection College of Jilin Medical University

Zitieren

APA

Qu, Z., Hao, F., Li, Z., Yang, L., Gao, H., Li, J., Chen, S., Wang, L., Xiu, Z., & Hu, C. (2025). Targeted Metabolic Alterations in Prostate Cancer: A Promising Therapeutic Strategy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00341

Vancouver

Qu Z, Hao F, Li Z, Yang L, Gao H, Li J, et al. Targeted Metabolic Alterations in Prostate Cancer: A Promising Therapeutic Strategy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00341

BibTeX
@article{Qu2025,
  author = {Qu, Zhanning and Hao, Feng and Li, Zhaojun and Yang, Liu and Gao, Hongxia and Li, Junying and Chen, Shuang and Wang, Liguo and Xiu, Zhiming and Hu, Cheng},
  title = {Targeted Metabolic Alterations in Prostate Cancer: A Promising Therapeutic Strategy},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00341}
}
Kostenlos starten →